ArticleScientific reports2024
Medication recommendation for Parkinson's disease based on dynamics of symptom progression.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Next-generation pharmacological strategies for Parkinson's disease: a systematic literature review of symptom management and disease modification.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- A modified Delphi consensus study to support and enhance Parkinson's disease management.Journal of Parkinson's disease · 2026Article
- Experimental Study on the Effects of Curcumin in Alleviating Oxidative Stress and Inducing Differentiation in Neural Stem Cells.International journal of food science · 2026Article
- Study of autocorrelations and uncertainties applied to patients with Parkinson's disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Parkinson's Disease (PD) is a chronic condition, with extensive research on initial medication selection for treatment, but limited guidance on long-term medication management. This study aims to identify optimal medication adjustment strategies based on patient clusters, focusing on either maximizing time spent in favorable health states or minimizing time spent in unfavorable ones while avoiding adverse effects. To guide treatment, we developed decision models using prescription dosages converted into standardized units for various medications. Using data from the Parkinson's Progression Markers Initiative, we employed a multivariate time-series clustering approach to capture symptom progression dynamics. This analysis identified four distinct clusters: two representing desirable and undesirable states, and two highlighting motor-focused and non-motor-focused failures across multiple domains. We developed two separate Markov Decision Process (MDP) models to address these dual objectives, which were then integrated into a comprehensive framework that suggests optimal actions and cautions against risky ones for each patient state. This model provides valuable insights for clinical decision-making by offering flexible guidance on adjusting medication intensity rather than prescribing specific medication types, enhancing its applicability in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.